| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 14,756 | 4,328 | ||
| Prepaid expenses and other current assets | 1,415 | 1,024 | ||
| Other receivables | 759 | 2,168 | ||
| Total current assets | 16,930 | 7,520 | ||
| Restricted cash | 5,390 | 5,390 | ||
| Property and equipment, net | 12,560 | 12,657 | ||
| Operating lease right-of-use asset | 39,917 | 40,504 | ||
| In-process research and development | 10,256 | 10,256 | ||
| Goodwill | 3,490 | 3,490 | ||
| Other assets | 973 | 973 | ||
| Total assets | 89,516 | 80,790 | ||
| Accounts payable and accrued liabilities | 1,999 | 1,540 | ||
| Accrued compensation | 1,843 | 1,584 | ||
| Convertible loan, current | 48,088 | 33,445 | ||
| Term debt, current | 82,992 | 78,891 | ||
| Current portion of operating lease liabilities | 4,525 | 4,488 | ||
| Other current liabilities | 503 | 137 | ||
| Total current liabilities | 139,950 | 120,085 | ||
| Term debt, non-current | 15,240 | - | ||
| Operating lease liabilities, net of current portion | 26,837 | 27,131 | ||
| Deferred tax liability | 3,077 | 3,077 | ||
| Total liabilities | 185,104 | 150,293 | ||
| Common stock, 0.01 par value 217,000,000 shares authorized 36,193,479 and 36,229,842 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 362 | 362 | ||
| Additional paid-in capital | 281,286 | 280,696 | ||
| Accumulated deficit | -377,236 | -350,561 | ||
| Total stockholders' deficit | -95,588 | -69,503 | ||
| Total liabilities and stockholders' deficit | 89,516 | 80,790 | ||
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)